Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma.

Abstract:

:Gliomas are lethal brain tumors that resist standard therapeutic approaches. Immunotherapy is a promising alternative strategy mostly developed in the context of glioblastoma. However, there is a need for implementing immunotherapy for grade II/III gliomas, as these are the most common CNS tumors in young adults with a high propensity for recurrence, making them lethal despite current treatments. We recently identified HLA-A2-restricted tumor-associated antigens by peptide elution from glioblastoma and formulated a multipeptide vaccine (IMA950) evaluated in phase I/II clinical trials with promising results. Here, we investigated expression of the IMA950 antigens in patients with grade II/III astrocytoma, oligodendroglioma or ependymoma, at the mRNA, protein and peptide levels. We report that the BCAN, CSPG4, IGF2BP3, PTPRZ1 and TNC proteins are significantly over-expressed at the mRNA (n = 159) and protein (n = 36) levels in grade II/III glioma patients as compared to non-tumor samples (IGF2BP3 being absent from oligodendroglioma). Most importantly, we detected spontaneous antigen-specific T cell responses to one or more of the IMA950 antigens in 100% and 71% of grade II and grade III patients, respectively (27 patients tested). These patients displayed T cell responses of better quality (higher frequency, broader epitope targeting) than patients with glioblastoma. Detection of spontaneous T cell responses to the IMA950 antigens shows that these antigens are relevant for tumor targeting, which will be best achieved by combination with CD4 epitopes such as the IDH1R132H peptide. Altogether, we provide the rationale for using a selective set of IMA950 peptides for vaccination of patients with grade II/III glioma.

journal_name

Oncoimmunology

journal_title

Oncoimmunology

authors

Dutoit V,Migliorini D,Ranzanici G,Marinari E,Widmer V,Lobrinus JA,Momjian S,Costello J,Walker PR,Okada H,Weinschenk T,Herold-Mende C,Dietrich PY

doi

10.1080/2162402X.2017.1391972

subject

Has Abstract

pub_date

2017-11-07 00:00:00

pages

e1391972

issue

2

eissn

2162-4011

issn

2162-402X

pii

1391972

journal_volume

7

pub_type

杂志文章
  • PD-L1 co-stimulation, ligand-induced TCR down-modulation and anti-tumor immunotherapy.

    abstract::PD-1 engagement on the surface of effector T cells strongly suppresses their cytotoxic function, which constitutes a major obstacle for T cell-mediated anti-tumor activities. Surprisingly, PD-1 is strongly upregulated in T cells, engaging its ligand PD-L1 during antigen presentation. However, our recent published data...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.1.1.17824

    authors: Karwacz K,Arce F,Bricogne C,Kochan G,Escors D

    更新日期:2012-01-01 00:00:00

  • IL-10 control of dendritic cells in the skin.

    abstract::Interleukin-10 (IL-10) is a potent immunomodulatory cytokine, whose cellular targets have not yet been precisely identified. Dendritic cell (DC)-specific IL-10 receptor knockout mice exhibit exaggerated T-cell reactivation in the skin, highlighting a key role of DCs in the maintenance of local immune homeostasis, beyo...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.23186

    authors: Clausen BE,Girard-Madoux MJ

    更新日期:2013-03-01 00:00:00

  • The PD1/PDL1 axis, a promising therapeutic target in aggressive breast cancers.

    abstract::Analysis of PDL1 mRNA expression in ∼5,500 breast cancers showed PDL1 upregulation in 38% of basal tumors and 38% of inflammatory breast cancers (IBC). Upregulation, associated with signs of strong cytotoxic local immune response, was associated with a better survival in the basal or triple-negative subtypes, and with...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2015.1085148

    authors: Bertucci F,Finetti P,Birnbaum D,Mamessier E

    更新日期:2015-08-31 00:00:00

  • Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma.

    abstract::Merkel cell carcinoma (MCC) is a rare skin cancer caused by Merkel cell polyomavirus (MCPyV) infection and/or ultraviolet radiation-induced somatic mutations. The presence of tumor-infiltrating lymphocytes is evidence that an active immune response to MCPyV and tumor-associated neoantigens occurs in some patients. How...

    journal_title:Oncoimmunology

    pub_type: 杂志文章,评审

    doi:10.1080/2162402X.2017.1338237

    authors: Schadendorf D,Nghiem P,Bhatia S,Hauschild A,Saiag P,Mahnke L,Hariharan S,Kaufman HL

    更新日期:2017-08-31 00:00:00

  • BRAF V600E mutation correlates with suppressive tumor immune microenvironment and reduced disease-free survival in Langerhans cell histiocytosis.

    abstract::Langerhans cell histiocytosis (LCH) is a neoplasm of myeloid origin characterized by a clonal proliferation of CD1a(+)/CD207(+) dendritic cells. Recurrent BRAF V600E mutation has been reported in LCH. In the present report, we confirm the feasibility of the high-specificity monoclonal antibody VE1 for detecting BRAF V...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2016.1185582

    authors: Zeng K,Wang Z,Ohshima K,Liu Y,Zhang W,Wang L,Fan L,Li M,Li X,Wang Y,Yu Z,Yan Q,Guo S,Wei J,Guo Y

    更新日期:2016-06-14 00:00:00

  • S100A4 promotes hepatocellular carcinogenesis by intensifying fibrosis-associated cancer cell stemness.

    abstract::A cancer-promoting role of fibrogenesis in the liver has long been speculated; however, the molecular mechanisms regarding this phenomenon are largely unknown. We demonstrated in our previous study that macrophage-derived S100A4 promotes liver fibrosis via activation of hepatic stellate cells; however, whether and how...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2020.1725355

    authors: Li Y,Wang J,Song K,Liu S,Zhang H,Wang F,Ni C,Zhai W,Liang J,Qin Z,Zhang J

    更新日期:2020-02-14 00:00:00

  • The crosstalk between acinar cells with Kras mutations and M1-polarized macrophages leads to initiation of pancreatic precancerous lesions.

    abstract::Recent studies on the processes that lead to the development of pancreatic cancer indicate that inflammatory macrophages have key functions in the initiation of pre-neoplastic lesions. Specifically, acquisition of an activating Kras mutation in pancreatic acinar cells leads to upregulation of intercellular adhesion mo...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2015.1008794

    authors: Storz P

    更新日期:2015-03-19 00:00:00

  • Synergistic inhibition of pancreatic cancer with anti-PD-L1 and c-Myc inhibitor JQ1.

    abstract::Human pancreatic ductal adenocarcinoma (PDAC) exhibits marginal responses to anti-PD-1/PD-L1 immunotherapy and its mechanism remains poorly understood. We have investigated the effect of anti-PD-L1 and c-Myc inhibition in PDAC. Using 87 patients with PDAC from our hospital database we found a significant correlation b...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2019.1581529

    authors: Pan Y,Fei Q,Xiong P,Yang J,Zhang Z,Lin X,Pan M,Lu F,Huang H

    更新日期:2019-03-01 00:00:00

  • Breaking the tolerance for tumor: Targeting negative regulators of TLR signaling.

    abstract::Tumors arise and progress in immunocompetent hosts presumably by activating tolerance mechanisms critical for normal homeostasis. Host immune cells can mount anti-tumor responses by activation of Toll-like receptors (TLRs). However, emerging data suggests that molecules that negatively regulate TLRs are exploited by t...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.18434

    authors: Standiford TJ,Keshamouni VG

    更新日期:2012-05-01 00:00:00

  • Longitudinal confocal microscopy imaging of solid tumor destruction following adoptive T cell transfer.

    abstract::A fluorescence-based, high-resolution imaging approach was used to visualize longitudinally the cellular events unfolding during T cell-mediated tumor destruction. The dynamic interplay of T cells, cancer cells, cancer antigen loss variants, and stromal cells-all color-coded in vivo-was analyzed in established, solid ...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.26677

    authors: Schietinger A,Arina A,Liu RB,Wells S,Huang J,Engels B,Bindokas V,Bartkowiak T,Lee D,Herrmann A,Piston DW,Pittet MJ,Lin PC,Zal T,Schreiber H

    更新日期:2013-11-01 00:00:00

  • Local immunomodulation combined to radiofrequency ablation results in a complete cure of local and distant colorectal carcinoma.

    abstract::Radiofrequency ablation (RFA) of colorectal liver metastases activates a specific T-cell response that is ineffective in avoiding recurrence. Recently, local immunomodulation garnered interests as a way to improve the immune response. We were interested in improving the RFA immune response priming to propose a curativ...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2018.1550342

    authors: Lemdani K,Mignet N,Boudy V,Seguin J,Oujagir E,Bawa O,Peschaud F,Emile JF,Capron C,Malafosse R

    更新日期:2019-01-10 00:00:00

  • HER2/neu DNA vaccination by intradermal gene delivery in a mouse tumor model: Gene gun is superior to jet injector in inducing CTL responses and protective immunity.

    abstract::DNA vaccines are potential tools for the induction of immune responses against both infectious disease and cancer. The dermal application of DNA vaccines is of particular interest since the epidermal and dermal layers of the skin are characterized by an abundance of antigen-presenting cells (APCs). The aim of our stud...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.22563

    authors: Nguyen-Hoai T,Kobelt D,Hohn O,Vu MD,Schlag PM,Dörken B,Norley S,Lipp M,Walther W,Pezzutto A,Westermann J

    更新日期:2012-12-01 00:00:00

  • NY-ESO-1 expression in sarcomas: A diagnostic marker and immunotherapy target.

    abstract::NY-ESO-1 (CTAG 1B) is highly expressed in the majority of synovial sarcomas and myxoid/round cell liposarcomas as well as in a subset of melanomas, but only rarely in other mesenchymal tumors. This points to a potential for using NY-ESO-1 in the differential diagnosis of these lesions. Furthermore, promising results h...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.21059

    authors: Lai JP,Rosenberg AZ,Miettinen MM,Lee CC

    更新日期:2012-11-01 00:00:00

  • Notch and TGFβ: Functional partners facilitating tumor progression.

    abstract::Cell signals integral to the tumor microenvironment influence cancer progression. Tumor-associated myeloid cells secrete pro-tumorigenic agents including, but not limited to, the potent cytokine transforming growth factor β (TGFβ). We have discovered a network of extrinsic signals including delta-like 4 (Dll4), Notch ...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.29029

    authors: Ohnuki H,Tosato G

    更新日期:2014-05-23 00:00:00

  • Trial watch: dietary interventions for cancer therapy.

    abstract::Dietary interventions have a profound impact on whole body metabolism, including oncometabolism (the metabolic features allowing cancer cells to proliferate) and immunometabolism (the catabolic and anabolic reactions that regulate immune responses). Recent preclinical studies demonstrated that multiple dietary changes...

    journal_title:Oncoimmunology

    pub_type: 杂志文章,评审

    doi:10.1080/2162402X.2019.1591878

    authors: Lévesque S,Pol JG,Ferrere G,Galluzzi L,Zitvogel L,Kroemer G

    更新日期:2019-04-03 00:00:00

  • Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia.

    abstract::Natural killer (NK)-cell count is predictive of chronic lymphoid leukemia (CLL) disease progression and their dysfunction is well documented, but the etiology of this is currently lacking. CLL cells have been shown to over-express HLA-E, the natural ligand for NKG2A expressed on NK-cells that generates a distinct nega...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2016.1226720

    authors: McWilliams EM,Mele JM,Cheney C,Timmerman EA,Fiazuddin F,Strattan EJ,Mo X,Byrd JC,Muthusamy N,Awan FT

    更新日期:2016-09-09 00:00:00

  • Co-localization of CD169+ macrophages and cancer cells in lymph node metastases of breast cancer patients is linked to improved prognosis and PDL1 expression.

    abstract::Breast cancer is the most common form of cancer in women worldwide. Although the survival among breast cancer patients has improved, there is still a large group of patients with dismal prognosis. One of the most important prognostic factors for poor prognosis is lymph node metastasis. Increasing knowledge concerning ...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2020.1848067

    authors: Björk Gunnarsdottir F,Auoja N,Bendahl PO,Rydén L,Fernö M,Leandersson K

    更新日期:2020-11-22 00:00:00

  • Vaccination of biliary tract cancer patients with four peptides derived from cancer-testis antigens.

    abstract::In the context of a Phase I clinical trial, the long-term vaccination of advanced biliary tract cancer patients with peptides derived from four distinct cancer-testis antigens resulted in remarkable disease stability and in the elicitation of antigen-specific T-cell responses. ...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.24882

    authors: Aruga A

    更新日期:2013-07-01 00:00:00

  • High sensitivity of cancer exome-based CD8 T cell neo-antigen identification.

    abstract::Recent data suggest that T-cell reactivity against tumor-specific neo-antigens may be central to the clinical efficacy of cancer immunotherapy. The development of personalized vaccines designed to boost T-cell reactivity against patient specific neo-antigens has been proposed largely on the basis of these findings. Wo...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.28836

    authors: van Buuren MM,Calis JJ,Schumacher TN

    更新日期:2014-05-14 00:00:00

  • SOX2-specific adaptive immunity and response to immunotherapy in non-small cell lung cancer.

    abstract::Immunotherapeutic strategies including the blockade of programmed death 1 (PD-1) receptors hold promise for the treatment of various cancers including non-small cell lung carcinoma (NSCLC). Preclinical data suggest that pre-existing tumor immunity is important for disease regression upon checkpoint blockade-based ther...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.25205

    authors: Dhodapkar KM,Gettinger SN,Das R,Zebroski H,Dhodapkar MV

    更新日期:2013-07-01 00:00:00

  • Depletion of B220+NK1.1+ cells enhances the rejection of established melanoma by tumor-specific CD4+ T cells.

    abstract::Five-year survival rates for patients diagnosed with metastatic melanoma are less than 5%. Adoptive cell transfer (ACT) has achieved an objective response of 50% by Response Evaluation Criteria in Solid Tumors (RECIST) in this patient population. For ACT to be maximally effective, the host must first be lymphodepleted...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2015.1019196

    authors: Wilson KA,Goding SR,Neely HR,Harris KM,Antony PA

    更新日期:2015-04-01 00:00:00

  • Flipping the script on macrophages in leiomyosarcoma.

    abstract::Macrophages promote the growth of leiomyosarcoma (LMS), a malignant soft-tissue tumor. CD47 on tumor cells binds to the macrophagic receptor signal regulatory protein α (SIRPα) and prevents phagocytosis. We showed that anti-CD47 monoclonal antibodies (mAbs) allow macrophages to engulf LMS cells and prevent tumor growt...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.20799

    authors: Edris B,Weiskopf K,Weissman IL,van de Rijn M

    更新日期:2012-10-01 00:00:00

  • Age-related mutational signature negatively associated with immune activity and survival outcome in triple-negative breast cancer.

    abstract::Triple-negative breast cancer (TNBC) is characterized by broad genomic and transcriptional heterogeneity and results in a worse prognosis than other breast cancer types. Here, we integrated genomic and transcriptomic data combined with clinicopathologic information from 538 patients with TNBC and identified four novel...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2020.1788252

    authors: Chen H,Chong W,Yang X,Zhang Y,Sang S,Li X,Lu M

    更新日期:2020-06-30 00:00:00

  • Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study.

    abstract::Objective:Ovarian cancer (OC) is often diagnosed at an advanced stage with two thirds of patients experiencing recurrent disease with a poor prognosis. Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) has shown curative potential in malignant melanoma, but has only been investigated scarcely in ot...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2018.1502905

    authors: Pedersen M,Westergaard MCW,Milne K,Nielsen M,Borch TH,Poulsen LG,Hendel HW,Kennedy M,Briggs G,Ledoux S,Nøttrup TJ,Andersen P,Hasselager T,Met Ö,Nelson BH,Donia M,Svane IM

    更新日期:2018-09-26 00:00:00

  • IL-32 induces indoleamine 2,3-dioxygenase+CD1c+ dendritic cells and indoleamine 2,3-dioxygenase+CD163+ macrophages: Relevance to mycosis fungoides progression.

    abstract::Mycosis fungoides (MF) progresses from patch to tumor stage by expansion of malignant T-cells that fail to be controlled by protective immune mechanisms. In this study, we focused on IL-32, a cytokine, highly expressed in MF lesions. Depending on the other cytokines (IL-4, GM-CSF) present during in vitro culture of he...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2016.1181237

    authors: Ohmatsu H,Humme D,Gonzalez J,Gulati N,Möbs M,Sterry W,Krueger JG

    更新日期:2016-05-05 00:00:00

  • A novel regulation of PD-1 ligands on mesenchymal stromal cells through MMP-mediated proteolytic cleavage.

    abstract::Whether fibroblasts regulate immune response is a crucial issue in the modulation of inflammatory responses. Herein, we demonstrate that foreskin fibroblasts (FFs) potently inhibit CD3+ T cell proliferation through a mechanism involving early apoptosis of activated T cells. Using blocking antibodies, we demonstrate th...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2015.1091146

    authors: Dezutter-Dambuyant C,Durand I,Alberti L,Bendriss-Vermare N,Valladeau-Guilemond J,Duc A,Magron A,Morel AP,Sisirak V,Rodriguez C,Cox D,Olive D,Caux C

    更新日期:2015-10-29 00:00:00

  • The consensus Immunoscore in phase 3 clinical trial (N0147) and impact on patient management decisions.

    abstract::The consensus Immunoscore is a routine assay quantifying the adaptive immune response within the tumor microenvironment. It has a prognostic value that has been confirmed in a phase 3 clinical trial (NCCTG N0147) in stage III colon cancers. Moreover, results from another phase 3 randomized trial revealed the predictiv...

    journal_title:Oncoimmunology

    pub_type: 杂志文章,评审

    doi:10.1080/2162402X.2020.1796003

    authors: Lanzi A,Sinicrope FA,Benson AB,Galon J

    更新日期:2020-07-20 00:00:00

  • Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody.

    abstract::Monoclonal antibodies (mAb) induce tumor regression through antibody-dependant cellular cytotoxicity (ADCC). We recently showed that an agonistic anti-CD137 mAb stimulates natural killer (NK) cells which have been activated by a tumor-specific mAb, resulting in increased ADCC against cancer cells. ...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.19974

    authors: Houot R,Kohrt H,Levy R

    更新日期:2012-09-01 00:00:00

  • Transforming the prostatic tumor microenvironment with oncolytic virotherapy.

    abstract::Prostate cancer (PCa) was estimated to have the second highest global incidence rate for male non-skin tumors and is the fifth most deadly in men thus mandating the need for novel treatment options. MG1-Maraba is a potent and versatile oncolytic virus capable of lethally infecting a variety of prostatic tumor cell lin...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2018.1445459

    authors: Atherton MJ,Stephenson KB,Tzelepis F,Bakhshinyan D,Nikota JK,Son HH,Jirovec A,Lefebvre C,Dvorkin-Gheva A,Ashkar AA,Wan Y,Stojdl DF,Belanger EC,Breau RH,Bell JC,Saad F,Singh SK,Diallo JS,Lichty BD

    更新日期:2018-03-27 00:00:00

  • Enhanced expression of CD39 and CD73 on T cells in the regulation of anti-tumor immune responses.

    abstract::Synthesis of extracellular adenosine by the ectonucleotidases CD39 and CD73 represents an important pathway of immune suppression in the tumor microenvironment. Using two mouse models (RET transgenic melanoma and Panc02 orthotopic pancreatic adenocarcinoma), we identified an elevated frequency of ectonucleotidase-expr...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2020.1744946

    authors: Shevchenko I,Mathes A,Groth C,Karakhanova S,Müller V,Utikal J,Werner J,Bazhin AV,Umansky V

    更新日期:2020-04-09 00:00:00